Business
Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a leading Illinois primary care provider with eight locations and tens of thousands of patients across Illinois, today announced that FMS is implementing Cardio Diagnostics’ solutions to identify patients at risk for coronary heart disease (CHD) events including heart attacks.\n\n\nHeart disease is the leading cause of death nationally. In Illinois, heart disease is not only the leading cause of death, but 29% of all deaths or more than one in every four deaths is attributable to heart disease. The \"Heart Attack Prevention\" initiative will leverage Cardio Diagnostics' advanced and highly sensitive blood-based epigenetic-genetic tests to risk stratify FMS’ patient population. According to the CDC, nearly 50% of Americans have at least one major cardiovascular risk such as diabetes, obesity, or hypertension. For many Americans, the first sign of CHD is a heart attack.\n\n\nFMS is implementing Cardio Diagnostics’ heart attack risk assessment test, Epi+Gen CHD, in at least 1,200 patients with CHD risk factors with BlueCross BlueShield Medicare, Medicaid, HMO and PPO health plans. By leveraging Cardio Diagnostics’ technology, in addition to understanding their patients’ risks, clinicians at FMS will be equipped with enhanced insights into the drivers of patients’ risks to aid in personalizing care. Ultimately, the goal of this initiative is to avert severe cardiac events and circumvent avoidable treatment costs that can spiral up to hundreds of thousands of dollars for heart attacks and downstream complications such as heart failure.\n\n\n\"With over 10,000 patient visits monthly across our eight clinics, FMS is committed to preventing avoidable cardiac events in our patients,\" said Dr. Bellucci-Jackson, Owner and lead clinician at FMS. \"Cardio Diagnostics' tests are simple to deploy in the clinics as they only require a blood draw and can provide advanced insights that our clinicians cannot obtain from current tools to identify the patients who need our help. Proactive risk assessment doesn't just save lives; it translates to tangible savings, considering the human and financial costs linked with surprise heart attacks.\"\n\n\n\"F...